Point mutations in the juxtamembrane domain of FLT3 define a new class of activating mutations in AML.
about
Structural and functional alterations of FLT3 in acute myeloid leukemiaAn overview on the role of FLT3-tyrosine kinase receptor in acute myeloid leukemia: biology and treatmentFLT3 D835/I836 mutations are associated with poor disease-free survival and a distinct gene-expression signature among younger adults with de novo cytogenetically normal acute myeloid leukemia lacking FLT3 internal tandem duplications.FLT3 tyrosine kinase inhibitors in acute myeloid leukemia: clinical implications and limitationsClinical outcome of de novo acute myeloid leukaemia patients with normal cytogenetics is affected by molecular genetic alterations: a concise reviewReversible resistance induced by FLT3 inhibition: a novel resistance mechanism in mutant FLT3-expressing cellsThe transcription factors STAT5A/B regulate GM-CSF-mediated granulopoiesis.Myeloid neoplasias: what molecular analyses are telling usSelective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1-2 study.Genetic tests to evaluate prognosis and predict therapeutic response in acute myeloid leukemia.Emerging FMS-like tyrosine kinase 3 inhibitors for the treatment of acute myelogenous leukemiaPhase I/II study of combination therapy with sorafenib, idarubicin, and cytarabine in younger patients with acute myeloid leukemia.The gene encoding the hematopoietic stem cell regulator CCN3/NOV is under direct cytokine control through the transcription factors STAT5A/B.Inhibition of FLT3 expression by green tea catechins in FLT3 mutated-AML cellsFLT3 inhibitors in the treatment of acute myeloid leukemia: the start of an era?Activating FLT3 mutants show distinct gain-of-function phenotypes in vitro and a characteristic signaling pathway profile associated with prognosis in acute myeloid leukemia.Clinical relevance of mutations and gene-expression changes in adult acute myeloid leukemia with normal cytogenetics: are we ready for a prognostically prioritized molecular classification?Receptor tyrosine kinase mutations in developmental syndromes and cancer: two sides of the same coinFLT3 mutations confer enhanced proliferation and survival properties to multipotent progenitors in a murine model of chronic myelomonocytic leukemia.SKLB-677, an FLT3 and Wnt/β-catenin signaling inhibitor, displays potent activity in models of FLT3-driven AML.High-throughput sequence analysis of the tyrosine kinome in acute myeloid leukemia.Structural and numerical variation of FLT3/ITD in pediatric AML.Detection of NPM1 exon 12 mutations and FLT3 - internal tandem duplications by high resolution melting analysis in normal karyotype acute myeloid leukemia.The use of molecular genetics to refine prognosis in acute myeloid leukemia.FLT3 activating mutations display differential sensitivity to multiple tyrosine kinase inhibitors.Repression of Gadd45alpha by activated FLT3 and GM-CSF receptor mutants contributes to growth, survival and blocked differentiation.FLT3 K663Q is a novel AML-associated oncogenic kinase: Determination of biochemical properties and sensitivity to Sunitinib (SU11248).Analysis of somatic mutations across the kinome reveals loss-of-function mutations in multiple cancer types.The Impact of FLT3 Mutations on the Development of Acute Myeloid Leukemias.Mutation profile of JAK2 transcripts in patients with chronic myeloproliferative neoplasias.Use of Sorafenib as an effective treatment in an AML patient carrying a new point mutation affecting the Juxtamembrane domain of FLT3.Tyrosine kinase inhibition increases the cell surface localization of FLT3-ITD and enhances FLT3-directed immunotherapy of acute myeloid leukemia.The importance of FLT3 mutational analysis in acute myeloid leukemia.Rare FLT3 deletion mutants may provide additional treatment options to patients with AML: an approach to individualized medicine.A novel point mutation within the juxtamembrane domain of the flt3 gene in acute myeloid leukemia.Identification of recurring tumor-specific somatic mutations in acute myeloid leukemia by transcriptome sequencing
P2860
Q24338964-48B96A80-95B7-473B-A00A-968FD92CFF07Q27027207-4735F563-2CE6-4BB3-8C0E-43CD7AA499B2Q27851415-4D8CE87D-D812-4BF6-B5AC-186A46D1809FQ28289859-1F5081CA-993E-49A5-A862-67D9654BFFA1Q28301344-D3FEE691-3676-4B95-A354-6C0094ED1899Q28477269-A1730189-7B48-4E17-8F46-9C487518AE2AQ30491770-95EB4C38-669D-4242-872F-39134D892BC3Q33354547-4D1A60F6-E1A4-4D48-AAF5-C6882FA9019DQ33442949-AB39B2F4-6437-4559-95C2-123B8DA2AA5AQ33555627-D4D03FB3-3775-43D6-8344-1EC0BF48FE85Q34004131-0283F03A-9AF5-42E5-9A3C-1D1DC81A4ACBQ34095013-E2E97652-B49B-458A-9124-D1A8233C7E4DQ34236608-245D5B68-5955-4E73-81F0-2C7B177F46FDQ34805329-E3A77F34-3F9C-438B-8163-18B37FCF6619Q35048217-C3A21A85-B84B-4743-8964-2356C08CA749Q35114397-6EDDC463-F007-403F-935E-64245B6CF16AQ35615901-4A15F6AF-2A26-41C5-8DAA-424536377758Q36065321-F530C9BA-CB96-47E4-AE70-2484008157E0Q36183556-9941FC59-DEE2-4A8D-91DF-6C7999C8C7A8Q36205970-D4BE4D2B-D219-42C5-9DFB-3243B931B3A9Q36591388-97C8C829-A409-4FDD-8C38-9EB64FD34B10Q36657987-8512913D-192A-4BB2-AC4F-FD6F924E76D0Q36840125-C5A76ED2-7380-4BA5-8251-BD43164B892EQ38198569-5FA6C5F5-3065-40B9-94E6-F4DC3FE459C6Q38721796-2C75D9F5-254C-4399-A6AB-41D528075B7DQ39893812-AFDA567F-278A-4CAF-9CCB-97A483EB4D96Q40228769-23912740-CC4C-476D-ACE3-6C3E617DC8FEQ41125698-3240B826-352F-4E34-91C5-E2817B87E791Q43070849-74B1AF93-38B9-4653-A4B5-F785AE966DE5Q43223369-8D55AF94-D9DB-493D-8CC0-ACEC3DC1BCEBQ43509669-A93C838C-DCAE-4E1E-AE51-ABEECF32B91DQ47818563-D2F7ACE4-107D-4675-906E-9D770B13FCBBQ48255430-63BC14F0-B95A-41FB-A2D5-A1A2A816EAE4Q54270008-D6EE5D62-C820-446C-92F5-A7C1A177BB50Q54645702-D2F38133-93B9-4D4B-85D2-7B373B7D926CQ57251802-E6511CC1-F283-43BD-B79F-DE118C1F432C
P2860
Point mutations in the juxtamembrane domain of FLT3 define a new class of activating mutations in AML.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
Point mutations in the juxtame ...... f activating mutations in AML.
@en
type
label
Point mutations in the juxtame ...... f activating mutations in AML.
@en
prefLabel
Point mutations in the juxtame ...... f activating mutations in AML.
@en
P2093
P1433
P1476
Point mutations in the juxtame ...... f activating mutations in AML.
@en
P2093
Carola Reindl
Joachim W Ellwart
Karsten Spiekermann
Katja Wenig
Ksenia Bagrintseva
Sridhar Vempati
Wolfgang Hiddemann
P304
P356
10.1182/BLOOD-2005-06-2596
P407
P577
2006-01-12T00:00:00Z